NSAID-associated gastroduodenal damage: does famotidine protection extend into the mid- and distal duodenum?
Eighteen healthy volunteers were included in a cross-over, double-blind study where 500 mg naproxen b.d. was given for 1 week with 20 mg famotidine b.d., 40 mg nocte or placebo. Endoscopic evaluation of the gastroduodenal mucosa was performed before and after each treatment period, with separate evaluation of the mid- and distal duodenum. 51Cr-EDTA-permeability tests were done to study effects on the mid- and distal gut, and, in addition, symptom registration was performed. The mucosal damage was significant in all treatment periods, and a statistically significant reduction was seen with 20 mg famotidine b.d. for erosive lesions in the stomach/duodenal bulb region as well as for the sum of damage score in the mid- and distal duodenum. The reduction was considerable in a few subjects with extensive duodenal damage. The reduction was considerable in a few subjects with extensive duodenal damage. Intestinal permeation increased significantly in all periods, and was not reduced by famotidine. Symptoms were modest and equal in all periods.
Aabakken
L
L
Medical Department, Ullevål Hospital, Oslo, Norway.
Bjørnbeth
B A
BA
Weberg
R
R
Viksmoen
L
L
Larsen
S
S
Osnes
M
M
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002860:Chromium Radioisotopes; D004311:Double-Blind Method; D004378:Duodenal Diseases / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control; D004386:Duodenum / Q000473:pathology; D004492:Edetic Acid / Q000493:pharmacokinetics; D016099:Endoscopy, Gastrointestinal; D015738:Famotidine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011897:Random Allocation; D013272:Stomach Diseases / Q000139:chemically induced*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002860:Chromium Radioisotopes; D015738:Famotidine; D004492:Edetic Acid